MedTrace Logo

Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy

NCT01435200 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2017-02-01

No results posted yet for this study

Summary

Can intravenous iron lower the rate of blood transfusion in gynecologic cancer patients receiving platinum based chemotherapy than oral iron?

Conditions

  • Gynecologic Cancer

Interventions

DRUG

Intravenous iron

Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Tarinee Manchana, MD · Chulalongkorn University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-10-31
Completion
2012-11-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01435200 on ClinicalTrials.gov